Zymeworks (ZYME)

Executive Summary

Zymeworks is a Vancouver-based biopharmaceutical company focused on developing innovative multifunctional biotherapeutics and antibody-drug conjugates (ADCs) for oncology, leveraging its proprietary Azymetric™ and ZymeLink™ platforms. The company's lead asset, zanidatamab (ZW25), is a bispecific antibody targeting HER2, advancing in multiple trials including a Phase 2 study in HER2-positive breast cancer and a Phase 3 combination regimen in biliary tract cancer. Additionally, Zymeworks has a robust early-stage pipeline with ADCs like ZW191 and ZW251 targeting novel solid tumors, and a royalty-driven partnership model with major pharma, providing non-dilutive funding and validation. With a recent successful completion of ZW49 Phase 1 and a strong cash position, Zymeworks is poised for multiple data readouts and regulatory milestones in the next 12-18 months, though near-term revenue remains dependent on partnership milestones.

Upcoming Catalysts (preview)

• Q2 2027Interim data from Phase 2 study of zanidatamab in HER2-positive breast cancer (NCT05035836)70% success
• Q3 2026FDA feedback on accelerated approval pathway for zanidatamab in biliary tract cancer50% success
• H2 2026Initial Phase 1 data for ADC candidates ZW191 and ZW25130% success